Clinical Trial Update: Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a dual JAK1/TYK2 inhibitor for cicatricial alopecia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cicatricial Alopecia

Drugs mentioned

• Dual JAK1/TYK2 inhibitor

Snippet

Sponsor: Emma Guttman | Conditions: Cicatricial Alopecia | Phase 2 | Status: COMPLETED